CytoMed Therapeutics Limited - Ordinary Shares (GDTC)
GDTC moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How GDTC actually reacts to news — the realized, point-in-time move the market made, measured across 101 labeled events over the last three years with zero look-ahead.
GDTC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 67 |
| 30-min | 0.00% | 37% | 79 |
| 60-min | -0.69% | 38% | 86 |
| to close | 0.00% | 47% | 98 |
| Middle 50% of GDTC reactions | -2.29% to +1.92% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 101 |
Half of all CytoMed Therapeutics Limited - Ordinary Shares news events land between -2.29% and +1.92% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GDTC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GDTC's baseline. Nothing else.
Recent GDTC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K CytoMed Therapeutics For: Oct 09 | SEC filing · Form 6-K | SEC EDGAR | — | +5.33% | |
| CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency | Press release | GlobeNewswire | +4.82% | -10.93% | |
| Form 6-K CytoMed Therapeutics For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +3.11% | +6.59% | |
| Form 6-K CytoMed Therapeutics For: Jun 23 | SEC filing · Form 6-K | SEC EDGAR | — | +1.41% | |
| Form 6-K CytoMed Therapeutics For: Jun 03 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.84% | |
| Form 6-K CytoMed Therapeutics For: May 15 | SEC filing · Form 6-K | SEC EDGAR | +1.90% | +22.12% | |
| Form 6-K CytoMed Therapeutics For: May 11 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.12% | |
| Form 6-K CytoMed Therapeutics For: Apr 14 | SEC filing · Form 6-K | SEC EDGAR | -0.99% | -1.01% | |
| Form 20-F CytoMed Therapeutics For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -1.96% | |
| Form 6-K CytoMed Therapeutics For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | — | -1.96% | |
| CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | Press release | GlobeNewswire | +3.79% | +0.72% | |
| Form 6-K CytoMed Therapeutics For: Jan 28 | SEC filing · Form 6-K | SEC EDGAR | — | +5.53% | |
| CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital | Press release | GlobeNewswire | -2.32% | -11.59% | |
| Form 6-K CytoMed Therapeutics For: Jan 13 | SEC filing · Form 6-K | SEC EDGAR | -2.32% | -11.59% | |
| CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia | Press release | GlobeNewswire | +2.58% | +2.78% | |
| Form 6-K CytoMed Therapeutics For: Dec 08 | SEC filing · Form 6-K | SEC EDGAR | +2.58% | +2.78% | |
| CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India | Press release | GlobeNewswire | -4.52% | -1.00% | |
| Form 6-K CytoMed Therapeutics For: Nov 18 | SEC filing · Form 6-K | SEC EDGAR | -4.52% | -1.00% | |
| CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy | Press release | GlobeNewswire | +20.95% | -19.37% | |
| Form 6-K CytoMed Therapeutics For: Nov 06 | SEC filing · Form 6-K | SEC EDGAR | +20.95% | -19.37% | |
| CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95% | Press release | GlobeNewswire | -1.05% | -6.62% | |
| Form 6-K CytoMed Therapeutics For: Oct 22 | SEC filing · Form 6-K | SEC EDGAR | -1.05% | -6.62% | |
| Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge | Press release | PR Newswire | +4.02% | +13.06% | |
| CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets | Press release | GlobeNewswire | -4.46% | +0.45% | |
| Form 6-K CytoMed Therapeutics For: Oct 14 | SEC filing · Form 6-K | SEC EDGAR | -4.46% | +0.45% | |
| CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic ?d T Cells in Acute Myeloid Leukemia | Press release | GlobeNewswire | +0.00% | -0.98% | |
| Form 6-K CytoMed Therapeutics For: Oct 02 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.98% | |
| Form 6-K CytoMed Therapeutics For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.51% | |
| Form 6-K CytoMed Therapeutics For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | — | +2.04% | |
| Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition | Press release | GlobeNewswire | — | +2.04% | |
| Form 6-K CytoMed Therapeutics For: Aug 18 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program | Press release | GlobeNewswire | — | — | |
| Form 6-K CytoMed Therapeutics For: Jul 21 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -4.76% | |
| Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies | Press release | GlobeNewswire | -0.94% | -4.76% | |
| Form 6-K CytoMed Therapeutics For: Jul 03 | SEC filing · Form 6-K | SEC EDGAR | — | +4.69% | |
| Form EFFECT CytoMed Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | — | +3.93% | |
| Form F-3 CytoMed Therapeutics | SEC filing · Form F-3 | SEC EDGAR | — | -1.42% | |
| Form 6-K CytoMed Therapeutics For: May 16 | SEC filing · Form 6-K | SEC EDGAR | — | -3.66% | |
| CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates | Press release | GlobeNewswire | — | +1.28% | |
| Form 20-F CytoMed Therapeutics For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | — | +1.28% | |
| Form 6-K CytoMed Therapeutics For: Apr 28 | SEC filing · Form 6-K | SEC EDGAR | — | +1.28% | |
| CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders | Press release | GlobeNewswire | — | -1.74% | |
| CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial | Press release | GlobeNewswire | -12.18% | -12.94% | |
| Form 6-K CytoMed Therapeutics For: Jan 06 | SEC filing · Form 6-K | SEC EDGAR | -12.18% | -12.94% | |
| Form S-8 CytoMed Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -4.17% | -5.13% | |
| Form 6-K CytoMed Therapeutics For: Dec 05 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -3.01% | |
| Form 6-K CytoMed Therapeutics For: Nov 20 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.92% | |
| Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies | Press release | GlobeNewswire | +0.00% | +0.92% | |
| CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant | Press release | GlobeNewswire | -1.45% | +1.21% | |
| Form 6-K CytoMed Therapeutics For: Oct 07 | SEC filing · Form 6-K | SEC EDGAR | -1.45% | +1.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GDTC section they belong to.
Where else GDTC is measured.
GDTC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CytoMed Therapeutics Limited - Ordinary Shares's median reaction calculated?
Every labeled GDTC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 101 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of GDTC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GDTC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.